Neuroprotection trials in Parkinson's disease: systematic review.
about
Biomarkers of Parkinson's disease: present and futureA review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's diseasePioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression.A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).Clinical progression in Parkinson disease and the neurobiology of axons.Review: management of Parkinson's disease.Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine.Treatment of Essential Tremor: Are there Issues We are Overlooking?Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease modelsBlood biomarker for Parkinson disease: peptoids.The futility study--Progress over the last decade.Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective.Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies.Aetiopathogenesis of Parkinson's disease.Milestones in Parkinson's disease therapeutics.Progression of motor symptoms in Parkinson's disease.Urate in Parkinson's disease: more than a biomarker?Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?An economic model of Parkinson's disease: implications for slowing progression in the United States.The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.Disease modification in Parkinson's disease.The current and projected economic burden of Parkinson's disease in the United States.Status and perspectives of neuroprotective therapies in glaucoma: the European Glaucoma Society White Paper.Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.Taurine protects dopaminergic neurons in a mouse Parkinson's disease model through inhibition of microglial M1 polarization.Multiple-Ascending-Dose Pharmacokinetics and Safety Evaluation of Baicalein Chewable Tablets in Healthy Chinese Volunteers.
P2860
Q24170134-B04A6D20-1B0C-4AAE-9A93-D1E7B5AA31B8Q27311651-A1F61DC3-9AC5-496A-B4E1-A2141339B277Q30357397-F6BD1D73-9D13-44D6-A73A-CBE27EDA9F56Q31105385-AD360B64-8732-4CE9-B9D7-DE31C65FAE09Q33753874-8642EA42-08A5-4FC2-AF05-915A517E4932Q34052764-DF0F907F-BF8D-4CBC-BD39-7C156C7FC894Q34332812-3F2A67BD-0B7C-4EAB-B579-C5BA78852215Q34585382-B0AC8FF3-8994-4698-B46D-3539EBA93DF8Q34635365-2762A065-593A-463B-AF17-4844ECB3C322Q35529695-6F583671-9DAB-4A2E-8ED1-B95518A76945Q36182485-B8FD399A-0295-49CA-8172-824B076385DBQ36264697-E84B64C3-8673-4857-BB16-1F937C4EE21EQ36968109-9FE51EB8-A1D9-4F18-BD07-767214FBB476Q37022421-C9347D46-E350-4AE5-8B9B-855B896F7CD9Q37506497-293331D9-21B7-4D63-87D1-60943722AC59Q37737068-E41CD179-E21C-4AED-B5FD-359D82BC586CQ37874190-5E34C92F-CCA5-481D-BFFF-60BCC71D9338Q37882596-03C42E0D-943D-4364-892E-DC8B8DA23DB6Q37974751-E1A749E0-B065-4372-8829-8B40C8CA8118Q38009670-8C864A46-FEFD-4949-A427-B59A2E7FD53AQ38021661-F3C7D3D7-5061-474C-8F63-4EFD3394EF50Q38081100-A22C2416-B6F3-4B53-B654-C162FDE9505CQ38852910-74AA23A3-87B1-4B13-A04D-2BC48EAAC2B0Q44266420-28A98A1E-647F-4B9F-A4A6-F02FFFA36044Q44713421-A3A9A4F2-3BEE-4118-B97D-8DA17BA369B5Q44988421-98A1F353-1669-4AA3-BE92-ABDCA610F913Q45786530-96BAA909-5E9F-4029-9EFD-EA20C08BC750Q48165108-645F3ABC-46A7-4C05-96E4-186EADDC217AQ52641738-5F1E59E5-E18A-4179-8F60-DAFE3B92C55AQ53917426-4861F68F-2B26-4FDF-97AF-3EEA81874051
P2860
Neuroprotection trials in Parkinson's disease: systematic review.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Neuroprotection trials in Parkinson's disease: systematic review.
@ast
Neuroprotection trials in Parkinson's disease: systematic review.
@en
Neuroprotection trials in Parkinson's disease: systematic review.
@nl
type
label
Neuroprotection trials in Parkinson's disease: systematic review.
@ast
Neuroprotection trials in Parkinson's disease: systematic review.
@en
Neuroprotection trials in Parkinson's disease: systematic review.
@nl
prefLabel
Neuroprotection trials in Parkinson's disease: systematic review.
@ast
Neuroprotection trials in Parkinson's disease: systematic review.
@en
Neuroprotection trials in Parkinson's disease: systematic review.
@nl
P2093
P2860
P356
P1433
P1476
Neuroprotection trials in Parkinson's disease: systematic review.
@en
P2093
Bernard M Ravina
John R Marler
Lesly A Pearce
Robert G Hart
Toby C Yaltho
P2860
P304
P356
10.1002/MDS.22432
P407
P577
2009-04-01T00:00:00Z